HC Wainwright Has Negative Estimate for ABEO Q2 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities research analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for Abeona Therapeutics in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of ($0.39) for the quarter, down from their previous estimate of ($0.37). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.80) EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.37 EPS.

ABEO has been the subject of a number of other reports. Wall Street Zen cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 15th. Oppenheimer started coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target on the stock. Alliance Global Partners reiterated a “buy” rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Finally, Stifel Nicolaus decreased their target price on Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Abeona Therapeutics Stock Up 2.0%

ABEO opened at $6.58 on Wednesday. The company has a fifty day moving average of $5.27 and a two-hundred day moving average of $5.56. The stock has a market capitalization of $321.10 million, a price-to-earnings ratio of -2.45 and a beta of 1.68. Abeona Therapeutics has a fifty-two week low of $3.93 and a fifty-two week high of $7.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.11.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in shares of Abeona Therapeutics by 74.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after acquiring an additional 28,606 shares during the last quarter. Wellington Management Group LLP purchased a new position in Abeona Therapeutics in the 4th quarter valued at $520,000. Trexquant Investment LP purchased a new stake in Abeona Therapeutics in the 4th quarter valued at approximately $382,000. Adage Capital Partners GP L.L.C. lifted its holdings in Abeona Therapeutics by 20.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock valued at $21,736,000 after acquiring an additional 652,366 shares during the period. Finally, Oxford Asset Management LLP purchased a new stake in Abeona Therapeutics during the fourth quarter worth about $118,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Abeona Therapeutics

In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of the company’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,355,322 shares in the company, valued at $6,478,439.16. This represents a 1.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark Alvino sold 8,000 shares of Abeona Therapeutics stock in a transaction on Friday, May 16th. The stock was sold at an average price of $5.68, for a total value of $45,440.00. Following the transaction, the director now owns 92,435 shares in the company, valued at approximately $525,030.80. This represents a 7.97% decrease in their position. The disclosure for this sale can be found here. Insiders own 6.90% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.